Freudenberg Medical, a global developer and manufacturer of specialty components and minimally invasive device solutions for the medical device and pharmaceutical industry, has acquired the majority of Hemoteq AG, a leading provider of surface coating technologies and related services for medical devices.
Hemoteq, based in Würselen, Germany, develops innovative coating solutions for combination products like drug eluting stents, as well as coatings for catheters and cochlear implants, and is a market leader for drug-coated balloon catheters. The company holds over 100 technology patents in innovative surface technologies.
Hemoteq provides comprehensive services from the development of the medical device to regulatory approval and serial production. Freudenberg Medical develops and manufactures minimally invasive systems as well as components made of silicone, thermoplastics and specialty metals. Those surfaces can be modified with active-ingredient coatings for optimal efficiency of the medical device.
Under the transaction, Freudenberg Medical will acquire 75 percent of Hemoteq AG from the current shareholders, Earlybird Venture Capital and Pinova Capital. The remaining shares are held by the founders of Hemoteq, Michael Hoffmann and Roland Horres, who together with the CFO, Thomas Löwen, will continue management of the company. Max Kley, President of Freudenberg Medical Europe and Specialty Components, will become Chairman of the Supervisory Board.